/

Sociétés

Io

Non vérifié

Io Therapeutics, Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieMédecine Santé Bien-être

4 communiqués de presse

Voir tous les communiqués de presse

06/12/2025

Biotechnologie

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma

Source

Io Therapeutics, Inc.

Émetteur

1.00

0

23/12/2024

Biotechnologie

Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

Source

Io Therapeutics, Inc.

Émetteur

1.00

0

11/12/2024

Biotechnologie

Médecine Santé Bien-être

Annonces Économiques

Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody checkpoint inhibitor

Source

Io Therapeutics, Inc.

Émetteur

1.00

0

08/11/2024

Biotechnologie

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers

Source

Io Therapeutics, Inc.

Émetteur

1.00

0

Followers

0

Compatibilité

0